Otsuka Holdings Co., Ltd. (4578.T) Stock

4578.T logo

Otsuka Holdings Co., Ltd.

4578.TJapan
Healthcare

Company profile

In Q3 2026 (the quarter ended September 30, 2026) revenue was 710.05 billion JPY, up 11.3% from a year before. Its largest business segment, Pharmaceuticals, brought in 71% of segment revenue in fiscal year 2025; North America was the largest region with 47%. In Q3 2026 it reported net income of 106.49 billion JPY, against net income of 124.13 billion JPY a year earlier. Otsuka Holdings reports about 37,758 full-time employees.

What stands out

  • Net income more than doubled in fiscal year 2024, from 121.62 billion JPY in fiscal year 2023.
  • Revenue and net income in fiscal year 2024 were the highest of the last 4 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Otsuka Holdings Co., Ltd.

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.

Largest shareholders

  • Otsuka Family9.642 %9.64%
  • Nomura Asset Management Co., Ltd.4.86%
  • Otsuka Holdings Co., Ltd.3.38%
  • Otsuka Holdings Employee Stock Ownership Plan2.31%
  • Amova Asset Management Co., Ltd.2.26%

Share of the company, as of September 25, 2026

Leadership

  • Makoto Inoue — President, CEO & Representative Director, 67
  • Yoshiro Matsuo — Executive Deputy President & Representative Director, 65
  • Yuko Makino — CFO & Executive Director, 64
  • Tomohiro Emura Ph.D. — Executive VP & Operating Officer of IR, Public Relations, and Sustainability Promotion
  • Chiaki Sakurai — Senior EVP, Operating Officer & Dir. of Nutraceutical Bus., Global Strat. and Planning Headquarters

What is Otsuka Holdings's largest business segment?

Pharmaceuticals, with 1.74 trillion JPY or 71% of segment revenue in fiscal year 2025. Next: Nutraceuticals (23%) and Others (5%).

Where does Otsuka Holdings make most of its revenue?

North America: 47% of revenue by region in fiscal year 2025, followed by Japan (29%).

What companies are similar to Otsuka Holdings?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Chugai Pharmaceutical Co., Ltd. (4519.T), Daiichi Sankyo Company, Limited (4568.T), Astellas Pharma Inc. (4503.T), Eisai Co., Ltd. (4523.T).

Has Otsuka Holdings made a profit in recent years?

Net income by fiscal year: FY2021, 125.46 billion JPY; FY2022, 133.91 billion JPY; FY2023, 121.62 billion JPY; FY2024, 343.12 billion JPY. It was profitable in each of these years.

How has Otsuka Holdings' revenue changed over the last 4 fiscal years?

Revenue by fiscal year: FY2021, 1.50 trillion JPY; FY2022, 1.74 trillion JPY; FY2023, 2.02 trillion JPY; FY2024, 2.33 trillion JPY.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees37,758
Founded1964
IPO DateDec 15, 2010
IPO StatusPublic
HeadquartersChiyoda, Japan
FoundersBusaburo Otsuka
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
2-9 Kanda-Tsukasamachi, Chiyoda, 101-0048
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Otsuka Holdings Co., Ltd. (4578.T)”, data as of Sep 30, 2026, https://dataporium.tech/stocks/4578.T

LinkedInLinkedInXXYouTubeYouTube